The alteration and potential function of the gut microbiota in various pathologies, 1 0 7 either as diagnostic biomarkers or contributors to pathogenesis, have attracted 1 0 8 increasing attention [14, 15] . For example, the gut bacterium Fusobacterium 1 0 9
nucleatum has been identified as a potent biomarker for improving the diagnostic immunotherapeutic drugs [16, 17] . Recently, we have assessed the role of GM in AF.
8
Our team characterized the associations of GM alterations and metabolic patterns with 1 1 9
AF by revealing the altered GM and bacteria-associated metabolites identified in AF 1 2 0 cases in a previous research [18] . We further designed a random forest disease 1 2 1 classifier based on abundances of co-abundance gene groups as variables for building 1 2 2 a microbiota-dependent discrimination model for AF detection. The results showed 1 2 3 that the differential gut microbiome signature could help diagnose AF, and the dynamic discrepancy in microbial diversity was observed between the non-RAF and 1 7 6 RAF groups, there was an increasing and aggravated tendency of shifts in the RAF 1 7 7
group, suggesting that patients experiencing recurrence after ablation might possess a 1 7 8 more advanced degree of GM dysbiosis than non-RAF individuals.
7 9
Meanwhile, considering the differences in clinical features such as age, T2DM 1 8 0 incidence, total cholesterol amounts, and glutamic-pyruvic transaminase levels as well 1 8 1 3 3 8 score and statin usage, as well as a combined model including the CAAP-AF score, 3 3 9 statin usage and Tax score were built (Table S8 ). After incorporating the clinical 3 4 0 factors of RAF, Tax score retained a significant association with RAF incidence 3 4 1 (HR=2.647, 95%CI: 1.038-6.749, P=0.041). Notably, the combined model had 
4 5
Then, using the enter method, logistic regression analysis with the clinical 1 4
[OR] =1, 885, 289.4390, [95] [96] [97] 333, 313, 606.5091; p=0 .0091; CAAP-AF 3 4 9 score, Coef=0.5445, OR=1.7237; 95%CI: 0.9477-3.1350; p=0.0744) ( Fig. 6 c) . Then, 3 5 0 a combined predictive model containing two predictive scores, named CAAP-AF-Tax 3 5 1 score, was constructed as follows: CAAP-AF-Tax score = 14.4496 × Tax score + 3 5 2 0.5445 × CAAP-AF + 2.2966, with values ranging from -12.4340 to 18.0986 3 5 3
(Additional files 10: Table S6 ). Patients with a score of -12.4340 and 18.0986 had 3 5 4 predicted recurrence risks of 3.98e-04% and 99.9999986%, respectively ( Fig. 6c ).
5 5
To assess the predictive value of the CAAP-AF- (AUC=0.9668, 95%CI: 0.9216-1.000, p=0.0011) was significantly higher (Fig. 6e ).
6 1
The predictive model was subsequently validated using the net reclassification index 3 6 2 (NRI). The NRI after adding the CAAP-AF score to the Tax score was 1.1509 3 6 3 (p=0.0003), while that after adding the Tax score to the CAAP-AF score was 1.5601 3 6 4 (p=1.0735e-06). Therefore, the Tax score theoretically improved the CAAP-AF 3 6 5 model for performance.
6 6
Then, the Kaplan-Meier method and log-rank test were carried out for assessing 3 6 7 the prognostic capacities of the developed CAAP-AF-Tax model, and AF cases were 3 6 8 assigned to high-and low-CAAP-AF-Tax score groups according to the optimal 3 6 9
cut-off of 0.633286. There was a significant difference in overall survival between the 3 7 0 high-and low-score groups (p < 0.0001, Fig. 6f , g).
7 1
To provide a quantitative method for predicting individual risk and RAF In the current study, we have acquired a series of intriguing results describing the 3 8 7
profiles of altered GM and metabolic patterns in AF patients more likely to 3 8 8 experience recurrence following radiofrequency ablation. The predictive model based 3 8 9
on the gut taxonomic signature was built for identifying patients at high risk of RAF.
9 0
We identified a gradually increasing degree of gut dysbiosis from non-AF to RAF, 3 9 1 and found multiple bacteria simultaneously enriched in non-RAF and RAF patients.
9 2
Meanwhile, imbalanced GM functions and metabolic alterations were observed, 3 9 3 which indicates the possible GM function in eliciting AF recurrence via interactions 3 9 4 with metabolites. This feature of GM is therefore suggested to be a 3 9 5 potent risk biomarker for the selection of patients who would benefit from 3 9 6 radiofrequency catheter ablation. It is recommended to include an additional focus 3 9 7 on GM profiling in the future development of ablation risk stratification and 3 9 8 strategies.
9 9
Strikingly, this study demonstrated that disordered GM constituted an 4 0 0 independent risk factor for AF recurrence. Catheter ablation is an efficient therapeutic 
4
Given the associations of 7-methylguanine and palmitoleic acid with GM 4 4 5
identified in the current work, these two metabolites are speculated to be potential 4 4 6 players mediating the impact of GM dysbiosis on RAF progression, at least in part.
7
Although it has not been assessed whether these two metabolites are directly produced 4 4 8 by the GM, evidence demonstrating a link between 7-methylguanine, palmitoleic acid 4 4 9
and GM is increasing. Palmitoleic acid belongs to the class of organic compounds low-grade inflammation is considered a potential mechanism contributing to AF. We contribute to AF recurrence through interactions with specific metabolites in the host.
7 6
In addition to the disparity between the non-RAF and RAF groups, similarities 4 7 7
shared by these groups were also revealed in the current study, which may be more 4 7 8
important and constitute key events in the onset-but not development-of AF.
7 9
Furthermore, bacterial organisms and metabolites commonly altered in the non-RAF Furthermore, sebacic acid belonging to medium-chain fatty acids is significantly less 4 8 6 abundant in both ulcerative colitis or Crohn disease patients [55] . Therefore, the 4 8 7
shared GM and metabolic profile demonstrated above may be associated with or even 4 8 8 contribute to AF onset.
8 9
These findings provided opportunities to take advantage of the GM for clinical 4 9 0 application for improving GM-related AF pathogenesis [56, 57] . For example, 
9 9
Engineering approaches like bacteriophages [66-68] specifically modifying gut 5 0 0 bacteria are also suggested. These extensive findings will pave the way to translate 5 0 1 GM use for clinical intervention, and more studies are imperative to evaluate its 5 0 2 clinical value in the context of AF.
0 3
In conclusion, the present findings provide a comprehensive description of Forty non-valvular persistent AF (psAF) patients who underwent radiofrequency 5 1 2 catheter ablation and 50 non-AF CTRs were included from our previous study [18] .
1 3
Fecal samples were collected before radiofrequency ablation; the gut microbiome 5 1 4
obtained before the ablation procedures was therefore utilized for predicting AF 5 1 5 recurrence risk. Metagenomic sequencing results of 50 non-AF controls' fecal 5 1 6 specimens previously assessed by our team were employed as controls. For the 50 5 1 7
non-AF controls, exclusion criteria were: previous heart failure; CAD; structural heart 5 1 8
disease; concurrent pathologies such as IBD, autoimmune disorders, liver disease, 5 1 9 kidney diseases or malignancy; antibiotic or probiotic use within a month prior to 5 2 0 enrolment. Patient baseline features were collected by face-to-face interviews and 5 2 1 from hospital records.
2 2
Catheter ablation and follow-up 5 2 3
In general, indications for AF ablation are symptomatic AF refractory or intolerant to 5 2 4 one or more Class I or III antiarrhythmics, as well as symptom-free AF before 5 2 5 administration of Class I or III antiarrhythmics [69] . A decision to perform ablation is 5 2 6
taken upon careful consideration of complication risks, success rate, substitute options 5 2 7 and patient preference.
2 8
Upon double-transseptal puncture under guidance of a 3D-electroanatomic 5 2 9
mapping system (CARTO 3; Biosense Webster, Inc., Diamond Bar, CA, USA), a 5 3 0
3D-reconstructed image of left atrium was generated with a circular mapping catheter 5 3 1 (NaviStarThermocool, Biosense Webster, Inc., Diamond Bar, CA, USA) followed by 5 3 2 merging to 3D VR cardiac CT scan. Following circumferential pulmonary vein were appended [4] . All catheter ablations were carried out by a single surgical team.
3 5
Following catheter ablation, patients underwent systematic follow-up and 5 3 6
12 lead electrocardiography at 3, 6, 12, and 18 months; respectively; an 5 3 7 2 1 electrocardiogram would be recorded in case a patient complained of discomfort.
3 8
Holter monitoring was performed at three-and six-months post-ablation and at all cases with persistent AF and some with paroxysmal AF would receive oral 5 5 0 antiarrhythmic drugs for a 3-month period. In the current work, amiodarone and 5 5 1
propafenone were administered to 30 (75%) and 7 (17.5%) individuals, respectively.
2
Antiarrhythmic drugs were stopped in case of RAF recurrence following 5 5 3 discontinuation for a period of time. During follow-up, the patients who experienced 5 5 4
RAF would resume with anti-arrhythmic medication; in case of persistent recurrent 5 5 5 episodes in spite of drug administration, a second ablative surgery would be offered.
6
Furthermore, according to current guidelines [1], the risk of stroke in AF patients 5 5 7
should be assessed by the CHA2DS2-VASc score. Generally, cases with no clinically with the first hit e≤10 × e-value were utilized for distinguishing taxonomic groups.
8 1
The taxonomic levels of different genes were assessed with the MEGAN software 5 8 2 (MEtaGenomeANalyzer); the abundance levels of different taxonomic groups were PCA: species 
